HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.

By BioPharma Dive · May 8, 2026 · via BioPharma Dive
Lilly, Gilead lead pharma’s M&A boom

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
dealsformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
DealsFiercePharma ↗
Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalys…
May 8, 2026
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
DealsFierceBiotech ↗
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
Roche is set to pay out a little more than $1 billion to acquire digital pathology specialist Path AI in a mov…
May 8, 2026
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
DealsFierceBiotech ↗
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s hea…
May 7, 2026